World Cancer-Treating Drugs Market Forecast 2017-2027
The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 194-page report you will receive 110 tables and 101 figures – all unavailable elsewhere.
The 194-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- World cancer-treating drugs market forecasts from 2017-2027
- This report also breaks down the revenue forecast for the world cancer-treating drugs market by its leading segments:
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Hormone Therapy
- This report discusses and forecasts revenues of the top 25 anti-cancer drugs:
- Avastin
- Herceptin
- Rituxan
- Gleevec
- Revlimid
- Alimta
- Velcade
- Erbitux
- Gardasil
- Zytiga
- Xeloda
- Tarceva
- Afinitor
- Sprycel
- Tasigna
- Sutent
- Nexavar
- Xgeva
- Zoladex
- Yervoy
- Vidaza
- Treanda
- Temodar
- Faslodex
- Abraxane
- Others
- This report provides individual revenue forecasts to 2027 for these regional and national markets:
- North America: US, Canada, Mexico
- South America: Brazil, Argentina, Paraguay, Brazil, Rest of South America
- Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
- Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
- Rest of World: Middle East, Africa, Other Countries
- This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the cancer-treating drugs market
- Our study discusses the selected leading companies that are the major players in the cancer-treating drugs market:
- AstraZeneca
- Merck & Co., Inc. (Merck)
- Novartis
- Amgen
- Bristol-Myers Squibb (BMS)
- GlaxoSmithKline (GSK)
- Johnson & Johnson (J&J)
- Roche
- Eli Lilly
- Celgene
Visiongain’s study is intended for anyone requiring commercial analyses for the world cancer-treating drugs market. You find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1 Report Overview
- 1.1 Global Cancer-Treating Drugs Overview
- 1.2 Research Methodology
- 1.2.1 Primary Research
- 1.2.2 Secondary Research
- 1.3 Market Evaluation & Forecasting Methodology
- 1.4 Global Cancer-Treating Drugs Market Segmentation
- 1.4.1 Global Top 25 Cancer Treating Drug Market
- 1.5 Overview of Findings
- 1.6 Why You Should Read This Report
- 1.7 How this report delivers?
- 1.8 Key Questions Answered by This Analytical Report
- 1.9 Frequently Asked Questions (FAQ)
- 1.10 Who is This Report For?
- 1.11 Associated Visiongain Reports
- 1.12 About Visiongain
- 2 Introduction to Cancer-Treating Drugs
- 2.1 The Physiology of Cancer – Causes and Effects
- 2.2 Uncontrolled Growth
- 2.3 Dedifferentiation
- 2.4 Invasiveness and Metastasis
- 2.5 Causes of Cancer
- 2.6 The Incidence and Prevalence of Cancer – Trends in the World
- 2.6.1 Incidence
- 2.6.2 Mortality
- 2.6.3 Survival – Improving Odds
- 2.7 The Developed World
- 2.7.1 The Developing World – More Must Be Done
- 2.8 Treating Tumours – How Can We Fight Back?
- 2.9 Chemotherapy – The Traditional Treatment
- 2.10 Hormone Therapies
- 2.11 Immunotherapy – A Magic Bullet?
- 2.11.1.1 Monoclonal Antibodies (mAbs)
- 2.11.1.2 Cancer Vaccines
- 2.11.1.3 Non-Specific Immunotherapies
- 2.11.1.4 Targeted Therapies
- 2.11.1.5 Differentiating Agents
- 3 Global Cancer-Treating Drug Market Forecast to 2027
- 4 Global Cancer Treating Drugs Market by Therapy: Market Forecast to 2027
- 4.1 Overview
- 4.2 Immunotherapy
- 4.3 Chemotherapy
- 4.4 Targeted Therapy
- 4.5 Hormone Therapy
- 5 Global Top 25 Cancer Treating Drugs: Market Forecast to 2027
- 5.1 Avastin - Roche
- 5.2 Herceptin - Roche
- 5.3 Rituxan – Roche
- 5.4 Gleevec - Novartis
- 5.5 Revlimid - Celgene
- 5.6 Alimta – Eli Lilly and Co.
- 5.7 Velcade – Takeda/ Janssen
- 5.8 Erbitux – Bristol Myers Squibb/ Merck KGaA/ Eli Lilly
- 5.9 Gardasil – Merck Sharp and Dohme Ltd
- 5.10 Zytiga - Janssen
- 5.11 Xeloda – Roche
- 5.12 Tarceva - Roche
- 5.13 Afinitor - Novartis
- 5.14 Sprycel – Bristol Myers Squibb
- 5.15 Tasigna – Novartis
- 5.16 Sutent – Pfizer
- 5.17 Nexavar – Bayer
- 5.18 Xgeva - Amgen
- 5.19 Zoladex - AstraZeneca
- 5.20 Yervoy – Bristol Myers Squibb
- 5.21 Vidaza - Celgene
- 5.22 Treanda Cephalon/ Teva
- 5.23 Temodar – Merck Sharp and Dohme Ltd
- 5.24 Faslodex - AstraZeneca
- 5.25 Abraxane – Celgene
- 5.26 Others
- 6 Regional Cancer Treating Drugs Market Forecasts to 2027
- 6.1 Regional Cancer Treating Drugs Market Forecast 2017-2027
- 6.2 North American Cancer Treating Drugs Market Forecast 2017-2027
- 6.2.1 US Cancer Treating Drugs Market Forecast 2017-2027
- 6.2.2 Canada Cancer Treating Drugs Market Forecast 2017-2027
- 6.2.3 Mexico Cancer Treating Drugs Market Forecast 2017-2027
- 6.3 South American Cancer Treating Drugs Market Forecast 2017-2027
- 6.3.1 Brazil Cancer Treating Drugs Market Forecast 2017-2027
- 6.3.2 Argentina Cancer Treating Drugs Market Forecast 2017-2027
- 6.3.3 Paraguay Cancer Treating Drugs Market Forecast 2017-2027
- 6.3.4 Bolivia Cancer Treating Drugs Market Forecast 2017-2027
- 6.3.5 Rest of South America Cancer Treating Drugs Market Forecast 2017-2027
- 6.4 European Cancer Treating Drugs Market Forecast 2017-2027
- 6.4.1 France Cancer Treating Drugs Market Forecast 2017-2027
- 6.4.2 Germany Cancer Treating Drugs Market Forecast 2017-2027
- 6.4.3 UK Cancer Treating Drugs Market Forecast 2017-2027
- 6.4.4 Spain Cancer Treating Drugs Market Forecast 2017-2027
- 6.4.5 Italy Cancer Treating Drugs Market Forecast 2017-2027
- 6.4.6 Rest of Europe Cancer Treating Drugs Market Forecast 2017-2027
- 6.5 Asia-Pacific Cancer Treating Drugs Market Forecast 2017-2027
- 6.5.1 China Cancer Treating Drugs Market Forecast 2017-2027
- 6.5.2 Japan Cancer Treating Drugs Market Forecast 2017-2027
- 6.5.3 India Cancer Treating Drugs Market Forecast 2017-2027
- 6.5.4 Australia Cancer Treating Drugs Market Forecast 2017-2027
- 6.5.5 Thailand Cancer Treating Drugs Market Forecast 2017-2027
- 6.5.6 Rest of Asia-Pacific Cancer Treating Drugs Market Forecast 2017-2027
- 6.6 Rest of World Cancer Treating Drugs Market Forecast 2017-2027
- 6.6.1 Middle East Cancer Treating Drugs Market Forecast 2017-2027
- 6.6.2 Africa Cancer Treating Drugs Market Forecast 2017-2027
- 6.6.2.1 Other Countries Cancer Treating Drugs Market Forecast 2017-2027
- 7 Cancer Treating Drugs Market, Qualitative Analysis, 2017-2027
- 7.1 SWOT Analysis of the Anti-Cancer Drugs Market
- 7.1.1 Strengths of the Market
- 7.1.1.1 The Rising Incidence of Cancer
- 7.1.1.2 Ample Treatment Options Available
- 7.1.2 Weaknesses
- 7.1.2.1 The Challenges of Drug Development
- 7.1.2.2 The Complex Nature of Cancer
- 7.1.2.3 Opportunities in the Anti-Cancer Drugs Market
- 7.1.2.3.1 The Advancement of Research
- 7.1.2.3.2 A Shift Towards Personalisation
- 7.1.2.4 Threats Facing the Anti-Cancer Drugs Market
- 7.1.2.4.1 The Threat of Regulation
- 7.2 STEP Analysis of the Anti-Cancer Drugs Market
- 7.2.1 Social Factors: The Cost of Living Longer
- 7.2.2 Technological Developments: Making the Market Move Forward
- 7.2.3 Economic Pressure: Treatment’s Hefty Price Tag
- 7.2.4 Political Issues: Governmental Involvement in Treatment
- 8 Leading Companies in Cancer Treating Drugs Market
- 8.1 AstraZeneca Plc
- 8.1.1 AstraZeneca Plc: Company Overview
- 8.1.2 AstraZeneca Plc: Product Portfolio
- 8.1.3 AstraZeneca Plc: Recent Developments
- 8.2 Merck & Co. Inc.
- 8.2.1 Merck & Co. Inc.: Company Overview
- 8.2.2 Merck & Co. Inc.: Product Portfolio
- 8.2.3 Merck & Co. Inc.: Recent Developments
- 8.3 Novartis AG
- 8.3.1 Novartis AG: Company Overview
- 8.3.2 Novartis AG: Product Portfolio
- 8.3.3 Novartis AG: Recent Developments
- 8.4 Amgen Inc.
- 8.4.1 Amgen Inc.: Company Overview
- 8.4.2 Amgen Inc.: Product Portfolio
- 8.4.3 Amgen Inc.: Recent Developments
- 8.5 Bristol-Myers Squibb
- 8.5.1 Bristol-Myers Squibb: Company Overview
- 8.5.2 Bristol-Myers Squibb: Product Portfolio
- 8.5.3 Bristol-Myers Squibb: Recent Developments
- 8.6 GlaxoSmithKline PLC (GSK Consumer Care)
- 8.6.1 GlaxoSmithKline PLC: Company Overview
- 8.6.2 GlaxoSmithKline PLC: Product Portfolio
- 8.6.3 GlaxoSmithKline PLC: Recent Developments
- 8.7 Johnson & Johnson
- 8.7.1 Johnson & Johnson: Company Overview
- 8.7.2 Johnson & Johnson: Product Portfolio
- 8.7.3 Johnson & Johnson: Recent Developments
- 8.8 F. Hoffmann-la Roche AG
- 8.8.1 F. Hoffmann-La Roche: Company Overview
- 8.8.2 F. Hoffmann-La Roche: Product Portfolio
- 8.8.3 F. Hoffmann-La Roche: Recent Developments
- 8.9 Eli Lilly and Company
- 8.9.1 Eli Lilly and Company: Company Overview
- 8.9.2 Eli Lilly and Company: Product Portfolio
- 8.9.3 Eli Lilly and Company: Recent Developments
- 8.10 Celgene Corporation
- 8.10.1 Celgene Corporation: Company Overview
- 8.10.2 Celgene Corporation: Product Portfolio
- 8.10.3 Celgene Corporation: Recent Developments
- 9 Conclusions
- 9.1 The Top 25 Drugs in the Cancer Treatment Market
- 9.2 Immunotherapies – The Future of the Market
- 9.3 Patent Expiries and the Impact of Biosimilars
- 9.4 The US – Still the Largest National Market
- 9.5 China and Brazil Will Lead the Emerging Markets
- 9.6 Treatment – It’s Personal
- 9.7 The Anti-Cancer Drug Pipeline Remains Strong
- 9.8 Concluding Remarks
- Appendices
- Visiongain Report Sales Order Form
- Appendix A
- About Visiongain
- Appendix B
- Visiongain report evaluation form
- List of Tables
- Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2017
- Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2017
- Table 3.1. Global Cancer-Treating Drugs Forecast ($bn, AGR%, CAGR%) 2017-2027
- Table 4.1. Global Cancer Treating Drugs Market Forecast, by Therapy ($bn, AGR%, CAGR%) 2017-2027
- Table 4.2. Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 4.3. Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, by Geography, ($bn, AGR%, CAGR%) 2017-2027
- Table 4.4. Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 4.5. Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027
- Table 4.6. Global Targeted Therapy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 4.7. Global Targeted Therapy Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027
- Table 4.8. Global Hormone Therapy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 4.9. Global Hormone Therapy Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027
- Table 5.1 Global Top 25 Cancer Treating Drugs Market, ($bn, AGR%, CAGR%) 2017-2027
- Table 5.2. Global Avastin Revenue Forecast ($bn, AGR%, CAGR%), 2017-2027
- Table 5.3. Global Herceptin Revenue Forecast ($bn, AGR%, CAGR%), 2017-2027
- Table 5.4. Global Rituxan Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.5 Global Gleevec Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.6 Global Revlimid Revenue ($bn, AGR%, CAGR%),2017-2027
- Table 5.7 Global Alimta Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.8 Global Velcade Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.9 Global Erbitux Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.10 Global Gardasil Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.11 Global Zytiga Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.12 Global Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%),2017-2027
- Table 5.13 Global Tarceva Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.14 Global Afinitor Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.15 Global Sprycel Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.16 Global Tasigna Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.17 Global Sutent Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.18 Global Nexavar Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.19 Global Xgeva Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.20 Global Zoladex Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.21 Global Yervoy Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.22 Global Vidaza Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.23 Global Treanda Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.24 Global Temodar Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.25 Global Faslodex Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.26 Global Abraxane Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 5.27 Global Others Revenue ($bn, AGR%, CAGR%), 2017-2027
- Table 6.1. Global Cancer Treating Drugs Market, by Geography ($bn, AGR%, CAGR%) 2017-2027
- Table 6.2. North America Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
- Table 6.3. US Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.4. Canada Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.5. Mexico Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.6. South America Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
- Table 6.7. Brazil Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.8. Argentina Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2016-2027
- Table 6.9. Paraguay Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.10. Bolivia Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.11. Rest of South America Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.12. European Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
- Table 6.13. France Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.14 Germany Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.15 UK Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.16. Spain Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.17. Italy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.18. Rest of European Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.19. Asia-Pacific Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
- Table 6.20. China Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
- Table 6.21. Japan Cancer Treating Drugs Market Forecast ($bn, AGR%, CAGR%) 2017-2027
- Table 6.22. India Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
